2018
DOI: 10.1159/000487753
|View full text |Cite
|
Sign up to set email alerts
|

Is There a Rationale behind Pharmacotherapy in Idiopathic Gynecomastia?

Abstract: Background/Aims: The aim of this research was to analyze digit ratio in relation to estrogen receptor (ER) and progesterone receptor (PR) expression and to verify digit ratio (2D: 4D) as a marker of ER and PR overexpression in the male breast. Methods: This study included 35 patients who underwent breast reduction due to the idiopathic form of gynecomastia. The average age of the studied individuals was 25.7 years (SD = 7.8). ER and PR expression was detected in breasts, and digit ratios were calculated in pat… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1

Citation Types

1
0
0

Year Published

2020
2020
2022
2022

Publication Types

Select...
2

Relationship

0
2

Authors

Journals

citations
Cited by 2 publications
(1 citation statement)
references
References 23 publications
(25 reference statements)
1
0
0
Order By: Relevance
“…Larger patient populations may enable identification of any plausible link between the degree of immunoexpression of these parameters and the severity of gynecomastia. The findings of our study are concurrent with the study by Kasielska‐Trojan A et al, in terms of a local paracrine expression of an estrogenic milieu, despite normal circulating oestrogens, in patients with idiopathic gynecomastia (Kasielska‐Trojan et al, 2018). The clinical implications of the study concur with available literature evidence asserting the superior efficacy of selective oestrogen receptor modulators over aromatase inhibitors in patients with idiopathic gynecomastia (Mannu et al, 2018; Narula & Carlson, 2014).…”
Section: Discussionsupporting
confidence: 92%
“…Larger patient populations may enable identification of any plausible link between the degree of immunoexpression of these parameters and the severity of gynecomastia. The findings of our study are concurrent with the study by Kasielska‐Trojan A et al, in terms of a local paracrine expression of an estrogenic milieu, despite normal circulating oestrogens, in patients with idiopathic gynecomastia (Kasielska‐Trojan et al, 2018). The clinical implications of the study concur with available literature evidence asserting the superior efficacy of selective oestrogen receptor modulators over aromatase inhibitors in patients with idiopathic gynecomastia (Mannu et al, 2018; Narula & Carlson, 2014).…”
Section: Discussionsupporting
confidence: 92%